ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026
Would the number of new cases of hereditary angioedema decrease due to declining fertility rates?
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema (HAE) is a rare, potentially life-threatening disorder caused by autosomal dominant mutations in the SERPING1 gene, leading to deficiency or dysfunction of C1 esterase inhibitor. Recent estimates of global HAE prevalence are 1.22 per 100,000 individuals. With total fertility rates (TFRs) decreasing worldwide, several developed countries are now well below the population replacement rate in an "ultra-low fertility" group. With the decrease in fertility, how rare diseases are approached should be re-examined. In this letter, we describe how continued and sustained declines in total fertility rate and population may influence the future number of new HAE cases. We also address disease-specific factors that may further influence future case count, including reproductive hesitancy related to autosomal dominant inheritance, estrogen-associated exacerbation of angioedema attacks, and potential fertility effects of complement dysregulation. These demographic considerations are relevant to clinicians, researchers, and pharmaceutical companies involved in HAE care. Better characterizing population changes in the context of reduced fertility rates may help inform long-term clinical planning and the development of novel therapies for HAE and other rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.